We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.

Nature | Dec 17, 1998

Fas ligand (FasL) is produced by activated T cells and natural killer cells and it induces apoptosis (programmed cell death) in target cells through the death receptor Fas/Apol/CD95. One important role of FasL and Fas is to mediate immune-cytotoxic killing of cells that are potentially harmful to the organism, such as virus-infected or tumour cells. Here we report the discovery of a soluble decoy receptor, termed decoy receptor 3 (DcR3), that binds to FasL and inhibits FasL-induced apoptosis. The DcR3 gene was amplified in about half of 35 primary lung and colon tumours studied, and DcR3 messenger RNA was expressed in malignant tissue. Thus, certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL.

Pubmed ID: 9872321 RIS Download

Mesh terms: Adult | Amino Acid Sequence | Antigens, CD95 | Apoptosis | Colonic Neoplasms | Cytotoxicity, Immunologic | DNA, Complementary | Expressed Sequence Tags | Fas Ligand Protein | Gene Amplification | Humans | Jurkat Cells | Killer Cells, Natural | Ligands | Lung Neoplasms | Membrane Glycoproteins | Molecular Sequence Data | Polymerase Chain Reaction | RNA, Messenger | Receptors, Cell Surface | Receptors, Tumor Necrosis Factor | Receptors, Tumor Necrosis Factor, Member 6b | Sequence Homology, Amino Acid | Tissue Distribution | Tumor Cells, Cultured